DIAGNOSTIC VALUE OF ENDOTHELIN 1 AND VASCULAR ENDOTHELIUM GROWTH FACTOR AND SIGNIFICANCE FOR DETERMINING THE THERAPEUTIC EFFECTIVENESS OF L-ARGININE ASPARATE IN CORONARY HEART DISEASE

Alyavi A.L.; Tulyaganova D.K.; Toshev B.B.

doi:10.5281/zenodo.10402819

DIAGNOSTIC VALUE OF ENDOTHELIN 1 AND VASCULAR ENDOTHELIUM GROWTH FACTOR AND SIGNIFICANCE FOR DETERMINING THE THERAPEUTIC EFFECTIVENESS OF L-ARGININE ASPARATE IN CORONARY HEART DISEASE

18.12.2023 International Scientific Journal "Science and Innovation". Series D. Volume 2 Issue 12

Alyavi A.L., Tulyaganova D.K., Toshev B.B.

Abstract. Coronary heart disease is the most common cause of death in the world. According to WHO, 740 million people die every year in the world, of which 13.2% die due to coronary heart disease. Therefore, the search for new markers that make it possible to predict coronary heart disease before an accident, as well as monitoring the therapeutic effectiveness of methods is one of the important and effective ways to reduce mortality. Through our study, we found that VEGF and ET-1 factor analysis is a very reliable candidate for predicting CAD and a very useful factor for evaluating the therapeutic effect of L-argiginine aspartate

Keywords: VEGF; ET-1; Myocardial infarction; cardiac ischemia; L-arginine aspartate; EZVD.

References:

1. Feng Y.-M., Verfaillie C., Yu H. Vascular Diseases and Metabolic Disorders. Stem Cells Int. 2016;2016:5810358. doi: 10.1155/2016/5810358. [PMC free article] [CrossRef] 2. Badimon L., Suades R., Crespo J., Padro T., Chiva-Blanch G. Diet, microparticles and atherothrombosis. Front. Biosci. Landmark Ed. 2018;23:432–457. doi: 10.2741/4598. [CrossRef] 3. Luo K., Long H., Xu B. Reduced apoptosis after acute myocardial infarction by simvastatin. Cell Biochem. Biophys. 2015;71:735–740. doi: 10.1007/s12013-014-0257-1. [CrossRef] 4. Mendis S., Thygesen K., Kuulasmaa K., Giampaoli S., Mähönen M., Ngu Blackett K., Lisheng L. Writing group on behalf of the participating experts of the WHO consultation for revision of WHO definition of myocardial infarction World Health Organization definition of myocardial infarction: 2008-09 revision. Int. J. Epidemiol. 2011;40:139–146. doi: 10.1093/ije/dyq165. [CrossRef] 5. Anisimov A., Tvorogov D., Alitalo A., Leppänen V.-M., An Y., Han E.C., Orsenigo F., Gaál E.I., Holopainen T., Koh Y.J., et al. Vascular endothelial growth factor-angiopoietin chimera with improved properties for therapeutic angiogenesis. Circulation. 2013;127:424–434. doi: 10.1161/CIRCULATIONAHA.112.127472. [CrossRef] 6. Tang J., Wang J., Kong X., Yang J., Guo L., Zheng F., Zhang L., Huang Y., Wan Y. Vascular endothelial growth factor promotes cardiac stem cell migration via the PI3K/Akt pathway. Exp. Cell Res. 2009;315:3521–3531. doi: 10.1016/j.yexcr.2009.09.026. [CrossRef] 7. Kucukardali Y., Aydogdu S., Ozmen N., Yonem A., Solmazgul E., Ozyurt M., Cingozbay Y., Aydogdu A. The relationship between severity of coronary artery disease and plasma level of vascular endothelial growth factor. Cardiovasc. Revasc. Med. 2008;9:66–70. doi: 10.1016/j.carrev.2007.11.005. [CrossRef] 8. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983–985. doi: 10.1126/science.6823562. [CrossRef] 9. Kobiyama K., Ley K. Atherosclerosis. Circ. Res. 2018;123:1118–1120. doi: 10.1161/CIRCRESAHA.118.313816. [PMC free article] [CrossRef] 10. Vempati P., Popel A.S., Mac Gabhann F. Extracellular regulation of VEGF: Isoforms, proteolysis, and vascular patterning. Cytokine Growth Factor Rev. 2014;25:1–19. doi: 10.1016/j.cytogfr.2013.11.002. [PMC free article] [CrossRef] 11. Holm P.W., Slart R.H.J.A., Zeebregts C.J., Hillebrands J.L., Tio R.A. Atherosclerotic plaque development and instability: A dual role for VEGF. Ann. Med. 2009;41:257–264. doi: 10.1080/07853890802516507. [CrossRef] Z., 12. Ferrara N., Gerber H.-P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003;9:669–676. doi: 10.1038/nm0603-669.